211 related articles for article (PubMed ID: 8758932)
1. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Shapiro RL; Duquette JG; Roses DF; Nunes I; Harris MN; Kamino H; Wilson EL; Rifkin DB
Cancer Res; 1996 Aug; 56(15):3597-604. PubMed ID: 8758932
[TBL] [Abstract][Full Text] [Related]
2. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
de Vries TJ; Kitson JL; Silvers WK; Mintz B
Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activation in melanocytic neoplasia.
Delbaldo C; Masouye I; Saurat JH; Vassalli JD; Sappino AP
Cancer Res; 1994 Aug; 54(16):4547-52. PubMed ID: 8044805
[TBL] [Abstract][Full Text] [Related]
4. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
6. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
7. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
Frandsen TL; Holst-Hansen C; Nielsen BS; Christensen IJ; Nyengaard JR; Carmeliet P; Brünner N
Cancer Res; 2001 Jan; 61(2):532-7. PubMed ID: 11212246
[TBL] [Abstract][Full Text] [Related]
8. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells.
Hearing VJ; Law LW; Corti A; Appella E; Blasi F
Cancer Res; 1988 Mar; 48(5):1270-8. PubMed ID: 2963689
[TBL] [Abstract][Full Text] [Related]
9. Spitz naevi may express components of the plasminogen activation system.
Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ
J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
de Vries TJ; Quax PH; Denijn M; Verrijp KN; Verheijen JH; Verspaget HW; Weidle UH; Ruiter DJ; van Muijen GN
Am J Pathol; 1994 Jan; 144(1):70-81. PubMed ID: 8291613
[TBL] [Abstract][Full Text] [Related]
11. Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice.
Ren CJ; Ueda F; Roses DF; Harris MN; Mignatti P; Rifkin DB; Shapiro RL
J Surg Res; 1998 Jul; 77(2):126-31. PubMed ID: 9733598
[TBL] [Abstract][Full Text] [Related]
12. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ
Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of premalignant and malignant lesions during the induction of mouse melanomas.
Berkelhammer J; Oxenhandler RW
Cancer Res; 1987 Mar; 47(5):1251-4. PubMed ID: 3102042
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse.
Ossowski L; Russo-Payne H; Wilson EL
Cancer Res; 1991 Jan; 51(1):274-81. PubMed ID: 1988089
[TBL] [Abstract][Full Text] [Related]
15. The role of lymphatic mapping and sentinel node biopsy in the management of atypical and anomalous melanocytic lesions.
Cochran AJ; Binder S; Morton DL
J Cutan Pathol; 2010 Apr; 37 Suppl 1():54-9. PubMed ID: 20482676
[TBL] [Abstract][Full Text] [Related]
16. Tumor progression in the human melanocytic system.
Kath R; Rodeck U; Menssen HD; Mancianti ML; Linnenbach AJ; Elder DE; Herlyn M
Anticancer Res; 1989; 9(4):865-72. PubMed ID: 2554787
[TBL] [Abstract][Full Text] [Related]
17. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
Xing RH; Mazar A; Henkin J; Rabbani SA
Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032
[TBL] [Abstract][Full Text] [Related]
18. Atypical cellular blue nevi (cellular blue nevi with atypical features): lack of consensus for diagnosis and distinction from cellular blue nevi and malignant melanoma ("malignant blue nevus").
Barnhill RL; Argenyi Z; Berwick M; Duray PH; Erickson L; Guitart J; Horenstein MG; Lowe L; Messina J; Paine S; Piepkorn MW; Prieto V; Rabkin MS; Schmidt B; Selim A; Shea CR; Trotter MJ
Am J Surg Pathol; 2008 Jan; 32(1):36-44. PubMed ID: 18162768
[TBL] [Abstract][Full Text] [Related]
19. Urokinase-type plasminogen activator deficiency (uPA-KO) prevented carotid artery ligation-induced vascular remodeling in mice.
Martin-McNulty B; Zhang L; da Cunha V; Vincelette J; Rutledge JC; Vergona R; Sullivan ME; Wang YX
Transl Res; 2007 Feb; 149(2):70-5. PubMed ID: 17240317
[TBL] [Abstract][Full Text] [Related]
20. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
